Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11876551rdf:typepubmed:Citationlld:pubmed
pubmed-article:11876551lifeskim:mentionsumls-concept:C0105770lld:lifeskim
pubmed-article:11876551lifeskim:mentionsumls-concept:C1420644lld:lifeskim
pubmed-article:11876551lifeskim:mentionsumls-concept:C1705000lld:lifeskim
pubmed-article:11876551lifeskim:mentionsumls-concept:C0007102lld:lifeskim
pubmed-article:11876551lifeskim:mentionsumls-concept:C0162832lld:lifeskim
pubmed-article:11876551lifeskim:mentionsumls-concept:C0017337lld:lifeskim
pubmed-article:11876551lifeskim:mentionsumls-concept:C1512430lld:lifeskim
pubmed-article:11876551lifeskim:mentionsumls-concept:C0332183lld:lifeskim
pubmed-article:11876551lifeskim:mentionsumls-concept:C1515926lld:lifeskim
pubmed-article:11876551pubmed:issue4lld:pubmed
pubmed-article:11876551pubmed:dateCreated2002-3-5lld:pubmed
pubmed-article:11876551pubmed:abstractTextHigh-frequency microsatellite instability (MSI-H) due to defective DNA mismatch repair (MMR) is a characteristic of the majority of tumors from kindreds with hereditary nonpolyposis colorectal cancer (HNPCC) and a subset of sporadic cancers. To better understand the molecular characteristics of colon cancers with MSI-H, we analyzed these cancers for alterations of genes, such as APC, beta-catenin, and TCF-4 genes, involved in the Wnt signaling pathway. Following the National Cancer Institute (NCI) criteria, 385 unselected colon cancers were classified as follows: 50 (13%) MSI-H tumors, 36 (9%) low-frequency MSI (MSI-L) tumors, and 299 (78%) microsatellite stable (MSS) tumors. The frequency of APC mutations was significantly lower in MSI-H tumors (9 out of 50) than in MSI-L (12 out of 20) and MSS (66 out of 100) tumors (P = 0.0005 and P < 0.0001, respectively). In contrast, the frequency of exon 3 mutations in the beta-catenin gene was higher in MSI-H tumors (10 out of 50) than in MSI-L tumors (0 out of 30; P = 0.0110) and MSS tumors (3 out of 100; P = 0.0010). Frameshift mutations in a (A)9 tract of the TCF-4 gene were detected in 44% (22 out of 50) of MSI-H tumors, but not in any of the 20 MSI-L tumors or 40 MSS tumors. In total, 78% of MSI-H tumors and 84% of the remaining tumors had at least one alteration in APC, beta-catenin, or the TCF-4 genes. Although further analysis is needed to functionally characterize the consequences of each of these alterations on beta-catenin/TCF target gene expression, our results suggest that the activation of the Wnt signaling pathway plays a pivotal role in colon tumorigenesis, irrespective of MSI status.lld:pubmed
pubmed-article:11876551pubmed:languageenglld:pubmed
pubmed-article:11876551pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11876551pubmed:citationSubsetIMlld:pubmed
pubmed-article:11876551pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11876551pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11876551pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11876551pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11876551pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11876551pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11876551pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11876551pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11876551pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11876551pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11876551pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11876551pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11876551pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11876551pubmed:statusMEDLINElld:pubmed
pubmed-article:11876551pubmed:monthDeclld:pubmed
pubmed-article:11876551pubmed:issn0392-9078lld:pubmed
pubmed-article:11876551pubmed:authorpubmed-author:ImaiKKlld:pubmed
pubmed-article:11876551pubmed:authorpubmed-author:HoriuchiSSlld:pubmed
pubmed-article:11876551pubmed:authorpubmed-author:FukushimaHHlld:pubmed
pubmed-article:11876551pubmed:authorpubmed-author:YamamotoHHlld:pubmed
pubmed-article:11876551pubmed:authorpubmed-author:ItouSSlld:pubmed
pubmed-article:11876551pubmed:authorpubmed-author:YeM ZMZlld:pubmed
pubmed-article:11876551pubmed:authorpubmed-author:IkoMMlld:pubmed
pubmed-article:11876551pubmed:issnTypePrintlld:pubmed
pubmed-article:11876551pubmed:volume20lld:pubmed
pubmed-article:11876551pubmed:ownerNLMlld:pubmed
pubmed-article:11876551pubmed:authorsCompleteYlld:pubmed
pubmed-article:11876551pubmed:pagination553-9lld:pubmed
pubmed-article:11876551pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:11876551pubmed:meshHeadingpubmed-meshheading:11876551...lld:pubmed
pubmed-article:11876551pubmed:meshHeadingpubmed-meshheading:11876551...lld:pubmed
pubmed-article:11876551pubmed:meshHeadingpubmed-meshheading:11876551...lld:pubmed
pubmed-article:11876551pubmed:meshHeadingpubmed-meshheading:11876551...lld:pubmed
pubmed-article:11876551pubmed:meshHeadingpubmed-meshheading:11876551...lld:pubmed
pubmed-article:11876551pubmed:meshHeadingpubmed-meshheading:11876551...lld:pubmed
pubmed-article:11876551pubmed:meshHeadingpubmed-meshheading:11876551...lld:pubmed
pubmed-article:11876551pubmed:meshHeadingpubmed-meshheading:11876551...lld:pubmed
pubmed-article:11876551pubmed:meshHeadingpubmed-meshheading:11876551...lld:pubmed
pubmed-article:11876551pubmed:meshHeadingpubmed-meshheading:11876551...lld:pubmed
pubmed-article:11876551pubmed:meshHeadingpubmed-meshheading:11876551...lld:pubmed
pubmed-article:11876551pubmed:meshHeadingpubmed-meshheading:11876551...lld:pubmed
pubmed-article:11876551pubmed:meshHeadingpubmed-meshheading:11876551...lld:pubmed
pubmed-article:11876551pubmed:meshHeadingpubmed-meshheading:11876551...lld:pubmed
pubmed-article:11876551pubmed:meshHeadingpubmed-meshheading:11876551...lld:pubmed
pubmed-article:11876551pubmed:meshHeadingpubmed-meshheading:11876551...lld:pubmed
pubmed-article:11876551pubmed:meshHeadingpubmed-meshheading:11876551...lld:pubmed
pubmed-article:11876551pubmed:meshHeadingpubmed-meshheading:11876551...lld:pubmed
pubmed-article:11876551pubmed:meshHeadingpubmed-meshheading:11876551...lld:pubmed
pubmed-article:11876551pubmed:meshHeadingpubmed-meshheading:11876551...lld:pubmed
pubmed-article:11876551pubmed:meshHeadingpubmed-meshheading:11876551...lld:pubmed
pubmed-article:11876551pubmed:meshHeadingpubmed-meshheading:11876551...lld:pubmed
pubmed-article:11876551pubmed:meshHeadingpubmed-meshheading:11876551...lld:pubmed
pubmed-article:11876551pubmed:year2001lld:pubmed
pubmed-article:11876551pubmed:articleTitleFrequent alterations of the beta-catenin and TCF-4 genes, but not of the APC gene, in colon cancers with high-frequency microsatellite instability.lld:pubmed
pubmed-article:11876551pubmed:affiliationFirst Dept. of Internal Medicine, Sapporo Medical University, Japan.lld:pubmed
pubmed-article:11876551pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11876551pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11876551lld:pubmed